According to a new report published by KD Market Insights, titled, “Antisense Oligonucleotides Market Insights, Trends, Opportunity & Forecast, 2023–2032,” the global antisense oligonucleotides market size is anticipated to witness moderate growth during the forecast period i.e., 2023-2032. The increasing adoption of antisense oligonucleotides in therapeutic applications for various genetic disorders and rare diseases. Additionally, advancements in molecular biology and gene editing technologies which are the major factors augmenting the growth of the global antisense oligonucleotides market. The global antisense oligonucleotides market is anticipated to grow at a high CAGR of 9.5% from 2023 to 2032. The market's revenue surged to $1.8 billion in 2022, and it is expected to further accelerate, reaching a notable $4.6 billion by 2032.
The increasing prevalence of genetic disorders and rare diseases fuels the demand for advanced and targeted therapies, such as antisense oligonucleotides. These oligonucleotides offer promising therapeutic options for various genetic conditions, ranging from muscular dystrophy to neurodegenerative diseases are further expected to create ample growth opportunities for the global antisense oligonucleotides market during the forecast period i.e., 2023-2032. Moreover, significant increase in research and development activities focused on autoimmune and chronic disorders has propelled market expansion. Increasing number of product launches by key players, is expected to contribute towards the market growth during the period.
The North America region accounted for the largest share in the global antisense oligonucleotides market in 2022. The region is further projected to continue dominating in the market during the forecast period. This can be attributed to the strong presence of pharmaceutical companies and biotechnology firms, coupled with robust research and development activities.
Download Exclusive Sample Report@ https://www.kdmarketinsights.com/sample/7418
According to therapeutic application, the cancer segment accounted for the largest market share in the antisense oligonucleotides market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.
The global antisense oligonucleotides market is segmented into drugs, therapeutic application, distribution channel and region. Based on drugs, the market is bifurcated into pegaptanib, eteplirsen, mipomersen, and others. Based on therapeutic application, it is classified into cancer, diabetes, ocular diseases, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, hemorrhagic fever viruses, HIV/AIDS, cytomegalovirus retinitis, and others. Based on distribution channel, it is classified into hospitals, retail pharmacies, and online pharmacies
The global antisense oligonucleotides market is analyzed across North America (U.S. & Canada), Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Indonesia, Thailand, Australia, New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of Latin America) and Middle East & Africa (GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, and Rest of Middle East & Africa).
Key Insights of Antisense oligonucleotides Market
- On the basis of therapeutic application, the cancer segment accounted for the largest market share in the antisense oligonucleotides market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.
- On the basis of region, North America accounted for the largest share in the global antisense oligonucleotides market in 2022. The region is further projected to continue dominating in the market during the forecast period.
- On the basis of region, Asia-Pacific is estimated to account for the second largest share in the market during the forecast period.
Some of the major antisense oligonucleotides companies profiled in the report include Ionis Pharmaceuticals Inc., Sarepta Therapeutics Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Antisense Therapeutics Ltd., Isarna Therapeutics GmbH, Arrowhead Pharmaceuticals Inc., Atlantic Pharmaceuticals Inc., Enzon Pharmaceuticals Inc., Bio-Path Holdings Inc., GlaxoSmithKline Plc., Gene Signal International SA., Geron Corporation, Gradalis Inc., ICO Therapeutics Inc., Aptose Biosciences Inc., Marina Biotech Inc., miRagen Therapeutics Inc., Synlogic Inc., OncoGenex Pharmaceuticals Inc., Pharmaxis Ltd., Rexahn Pharmaceuticals Inc., Regulus Therapeutics Inc., and Rxi Pharmaceuticals Inc.
Browse Full Report Along With Facts and Figures@ https://www.kdmarketinsights.com/reports/antisense-oligonucleotides-market/7418
Browse Trending Reports:
https://www.kdmarketinsights.com/reports/transport-patient-monitor-market/7411
https://www.kdmarketinsights.com/reports/mobile-hemodialysis-machine-market/7408
https://www.kdmarketinsights.com/reports/micrographic-camera-market/7407
https://www.kdmarketinsights.com/reports/biostimulants-market/2048
https://www.kdmarketinsights.com/reports/medical-and-diagnostic-laboratory-services-market/7409
About KD Market Insights
KD Market Research Company is a reputable and industry-leading market research firm that offers insightful insights, Analytics, and Research Reports for a variety of industries. With an emphasis on providing accurate and actionable market insights and data, our team of experienced research analysts conducts exhaustive research to assist businesses in making informed decisions. Whether you require market forecasts, competitive analysis, or the identification of trends, we offer comprehensive solutions tailored to your specific requirements. Stay ahead of the competition with the dependable market research services of KD Market Research Company.
Contact Us:
KD Market Insights
150 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: sales@kdmarketinsights.com
Website: www.kdmarketinsights.com
